Highlights

  • EMVision reported favourable aeromedical feasibility and usability study outcomes.
  • Scan quality remained unaffected across 13 patient transfers during flight conditions.
  • The study involved collaboration with the Royal Flying Doctor Service and Australian Stroke Alliance.
  • EMVision received the final AUD 400,000 milestone payment under its Australian Stroke Alliance agreement.
  • The company continues progressing toward production-equivalent commercial units and regulatory testing.

EMVision Medical Devices Ltd (ASX:EMV) shares moved modestly higher during the morning session on 27 May 2026 after the company released favourable results from an aeromedical feasibility and usability study involving its First Responder Brain Scanner.

The stock gained 1.46% to AUD 1.74 following the update, although shares remain slightly lower over the past 12 months. Investor attention appeared to focus on the company’s progress in validating the use of its portable neurodiagnostic technology across rural, remote and pre-hospital stroke care environments.

The latest announcement outlined operational testing conducted in collaboration with the Royal Flying Doctor Service (RFDS), Australian Stroke Alliance (ASA) and South Australian Ambulance Service (SAAS). According to the company, the study demonstrated that the device could be effectively deployed and operated in aeromedical retrieval settings without material impact on scan quality.

The results are considered important because they support one of the company’s intended commercial use cases — enabling faster stroke assessment in locations where access to traditional neuroimaging infrastructure can be delayed.

Bold Focus on Rural and Remote Stroke Care

EMVision’s First Responder Brain Scanner is being developed as a portable, non-invasive neurodiagnostic device designed to support rapid stroke assessment at the point of care.

Stroke diagnosis often depends on timely neuroimaging to determine the appropriate treatment pathway. However, patients in regional and remote areas can experience delays in reaching hospitals equipped with CT imaging systems, particularly where long-distance retrieval is required.

The company stated that aeromedical retrieval settings represent a critical opportunity for earlier triage and treatment decision-making, especially during the initial period following patient contact.

According to EMVision, the recent study provides real-world evidence supporting the feasibility of using the device during aeromedical transport, which may help address existing gaps in rural stroke care.

The company noted that the findings help de-risk this particular use case as it advances toward future commercialisation and regulatory pathways.

Study Conducted Across Real-World Retrieval Environments

The aeromedical study was designed as a single-arm workflow integration trial focused on assessing operational feasibility and usability.

A total of 17 adult participants undergoing aeromedical transport were enrolled in the study. The First Responder Brain Scanner was dispatched across 15 transfers involving 12 separate airstrips located between 125 kilometres and 371 kilometres from Adelaide Airport.

Importantly, scans were conducted across a variety of operational environments, including airport tarmacs, stationary aircraft cabins and clinical settings.

This approach allowed EMVision and its collaborators to evaluate how the device performed under practical field conditions rather than solely within controlled laboratory environments.

The company reported that scan data quality remained consistent and comparable to scans conducted at its own facilities, despite the variable and demanding conditions associated with aeromedical transport.

Several operational variables were monitored during the study, including vibration, tilt angle, temperature, device movement, Inflation pressure and scan performance.

According to the company, none of these factors materially affected scan data quality.

Operator and Patient Feedback Viewed Positively

A notable aspect of the study involved feedback from Royal Flying Doctor Service flight nurses, who served as the end users operating the scanner during the retrieval exercises.

The nurses completed usability assessments covering areas such as device preparation, participant set-up and scanner operation.

EMVision stated that feedback across these categories was largely favourable, with operators indicating the scanner was practical, intuitive and suitable for aeromedical use.

The median scan duration recorded during the study was approximately 5 minutes and 7 seconds, including a built-in three-minute redundant scan sequence.

The company also noted that scan duration is expected to become shorter in future production-equivalent commercial devices currently under development.

Patient experience was another focus of the study outcomes. According to EMVision, 92% of participants reported feeling calm during the scanning process, while all participants indicated they would be comfortable seeing the device used on a family member.

These findings may prove relevant as the company continues refining usability and workflow integration ahead of larger-scale clinical and regulatory activities.

Commercial and Regulatory Progression Continues

EMVision stated that the latest study outcomes support the transition toward production-equivalent commercial units for the First Responder Brain Scanner.

The company explained that these future units are being designed to improve upon the first-generation emu™ Brain Scanner platform across performance, usability and manufacturability metrics.

Importantly, the production-equivalent systems are expected to support upcoming diagnostic performance testing, substantial equivalence assessments and additional data collection activities required along the regulatory pathway.

The company also highlighted that broader pre-hospital evaluation programs remain underway.

In addition to the aeromedical retrieval study, EMVision confirmed that its Mobile Stroke Unit study is nearing completion ahead of future reporting.

Preparations are also progressing for another upcoming study involving deployment in standard road ambulance environments.

Collectively, these programs are intended to generate operational and clinical evidence across multiple pre-hospital stroke care scenarios.

International Exposure Adds Visibility

EMVision also used the update to highlight growing engagement with the international stroke and neurology community.

The company’s technology platform, including the First Responder Brain Scanner, was recently featured at the European Stroke Organisation Conference 2026.

Presentations involving the technology were delivered by representatives from Oslo University Hospital as well as the Royal Flying Doctor Service and Australian Stroke Alliance during associated PRESTO satellite meetings.

While the company did not announce commercial agreements linked to these events, the international exposure may contribute to broader awareness of the technology platform within the clinical community.

As medical device companies continue progressing toward commercialisation, engagement with clinicians, researchers and healthcare organisations often plays an important role in adoption and validation pathways.

Milestone Funding Supports Development Activities

Alongside the study outcomes, EMVision confirmed it had received the final AUD 400,000 non-dilutive milestone payment under its Australian Stroke Alliance Project Agreement.

The funding was provided through the Medical Research Future Fund (MRFF).

Non-dilutive funding arrangements are often viewed positively by investors because they support development activities without requiring the issuance of additional Equity.

The company did not disclose updated cash balance figures in this announcement, although the milestone payment contributes additional support for ongoing development and research programs.

About EMVision Medical Devices

EMVision Medical Devices is an Australian medical technology company focused on developing portable neurodiagnostic devices aimed at improving the speed and accessibility of stroke diagnosis.

The company’s product pipeline centres on non-invasive and portable scanning technologies designed for use at the point of care, including pre-hospital and emergency environments.

Its broader objective is to support earlier diagnosis and treatment decisions for stroke and other time-sensitive neurological conditions.

EMVision currently operates from offices located in Sydney and Brisbane and continues advancing clinical, operational and regulatory development programs tied to its technology platform.

What This Means for Investors

EMVision’s latest update provides additional evidence supporting the practical deployment of its First Responder Brain Scanner in aeromedical retrieval settings, an area viewed as an important future commercial opportunity.

The study outcomes suggest the device can operate effectively across real-world environments while maintaining scan quality and usability standards.

Investors are likely to continue monitoring the company’s progression toward production-equivalent commercial units, future clinical studies and regulatory milestones.

With additional testing programs underway across ambulance and pre-hospital settings, the company continues building operational evidence aimed at supporting broader adoption of its stroke diagnostic technology.